Skip to main content

Table 1 Characteristics of patients with choroidal bulging and Vogt-Koyanagi-Harada disease in non-acute uveitic stage

From: Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage

Patient, gender, age (years)

Studied eye

Disease duration (months)

Choroidal bulging

Signs of disease activity

Changes observed at subsequent FU visit

Location

Change

ACC

Hyperfluorescence of OD on FA

Dark dots on ICGA

Medication adjustment after CB visit

 

1, M, 65

RE

117

Outer nasal

+139 μm (+74%)

+/2

+

None

Month 137: improvement of CB (−145 μm), increase in ACC (+), absence of dark dots (−)

2, F, 54

RE

10

Outer nasal

+131 μm (+139%)

+

++

+++

Tapering of oral prednisone (15 to 10 mg/day)

Month 17: worsening of CB (+66 μm), increase in OD hyperfluorescence (+++), localized increase of dark dots

LE

10

Outer nasal

+138 μm (+107%)

+

++

+++

Month 17: improvement of CB (−101 μm), decrease in OD hyperfluorescence (+/2), decrease of dark dots (+)

3, F, 53

LE

32

Parafoveal

+215 μm (+74%)

+

+

++

Substitution for mycophenolate mofetil 1.5 g/day

Month 35: disappearance of CB (−74 μm), maintenance in OD hyperfluorescence (+), attenuation of dark dots

  1. These characteristics were observed by the time the choroidal bulging was identified on enhanced-depth imaging spectral optical coherence tomography. ACC, anterior chamber cells; CB, choroidal bulging; F, female; FA, fluorescein angiography; FU, follow-up; ICGA, indocyanine green angiography; LE, left eye; M, male; OD, optic disc; RE, right eye.